Clozapine

Source: Wikipedia, the free encyclopedia.
Not to be confused with clonazepam or clonidine.

Clozapine
Skeletal formula of clozapine
Stick-and-ball model of the clozapine molecule
Clinical data
Trade namesClozaril, Leponex, Versacloz, others[1]
AHFS/Drugs.comMonograph
MedlinePlusa691001
License data
Pregnancy
category
  • AU: C
Routes of
administration		By mouth, intramuscular injection
Drug classAtypical antipsychotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability60 to 70%
MetabolismLiver, by several CYP isozymes
Elimination half-life4 to 26 hours (mean value 14.2 hours in steady state conditions)
Excretion80% in metabolized state: 30% biliary and 50% kidney
Identifiers
  • 8-Chloro-11-(4-methylpiperazin-1-yl)-5H-dibenzo[b,e][1,4]diazepine
JSmol)
Melting point183 °C (361 °F)
Solubility in water0.1889[5]
  • CN1CCN(CC1)C2=Nc3cc(ccc3Nc4c2cccc4)Cl
  • InChI=1S/C18H19ClN4/c1-22-8-10-23(11-9-22)18-14-4-2-3-5-15(14)20-16-7-6-13(19)12-17(16)21-18/h2-7,12,20H,8-11H2,1H3 checkY
  • Key:QZUDBNBUXVUHMW-UHFFFAOYSA-N checkY
  (verify)

Clozapine is a psychiatric medication and is the first atypical antipsychotic (also called second-generation antipsychotic) to be discovered.[6] It is primarily used to treat people with schizophrenia and schizoaffective disorder who have had an inadequate response to two other antipsychotics or who have been unable to tolerate other drugs due to extrapyramidal side effects. It is also used for the treatment of psychosis in Parkinson's disease.[7][8]

Clozapine is recommended by multiple international treatment guidelines, after resistance to two other antipsychotic medications and is the only treatment likely to result in improvement if two (or one

seizures, myocarditis (inflammation of the heart), hyperglycemia (high blood glucose levels), and constipation. The use of this drug can rarely result in clozapine-induced gastric hypomotility syndrome which may lead to bowel obstruction and death, and in older people with psychosis, as a result of dementia it may lead to an increased risk of death.[21][22] The mechanism of action is not entirely clear in the current medical literature.[19]

History

Clozapine was synthesized in 1958 by Wander AG, a Swiss pharmaceutical company, based on the chemical structure of the tricyclic antidepressant

Sandoz.[23] Further trials took place in 1972 when clozapine was released in Switzerland and Austria as Leponex.[23] Two years later it was released in West Germany and in Finland in 1975.[23] Early testing was performed in the United States around the same time.[23] In 1975, 16 cases of agranulocytosis leading to 8 deaths in clozapine-treated patients, reported from 6 hospitals mostly in southwestern Finland, led to concern.[25] Analysis of the Finnish cases revealed that all the agranulocytosis cases had occurred within the first 18 weeks of treatment and the authors proposed blood monitoring during this period.[26] The rate of agranulocytosis in Finland appeared to be 20 times higher than in the rest of the world and there was speculation that this may have been due a unique genetic variant in the region.[27][28][29] Whilst the drug continued to be manufactured by Sandoz
, and remained available in Europe, development in the U.S. halted.

Interest in clozapine continued in an investigational capacity in the United States because, even in the 1980s, the duration of hospitalisation, especially in State Hospitals for those with treatment resistant schizophrenia might often be measured in years rather than days.[23] The role of clozapine in treatment resistant schizophrenia was established by the landmark Clozaril Collaborative Study Group Study #30 in which clozapine showed marked benefits compared to chlorpromazine in a group of patients with protracted psychosis and who had already shown an inadequate response to other antipsychotics. This involved both stringent blood monitoring and a double-blind design with the power to demonstrate superiority over standard antipsychotic treatment. The inclusion criteria were patients who had failed to respond to at least three previous antipsychotics and had then not responded to a single blind treatment with haloperidol (mean dose 61 mg +/− 14 mg/d). Two hundred and sixty-eight were randomised were to double blind trials of clozapine (up to 900 mg/d) or chlorpromazine (up to 1800 mg/d). 30% of the clozapine patients responded compared to 4% of the controls, with significantly greater improvement on the Brief Psychiatric Rating Scale, Clinical Global Impression Scale, and Nurses' Observation Scale for Inpatient Evaluation; this improvement included "negative" as well as positive symptom areas.[30] Following this study, the US Food and Drug Administration (FDA) approved its use in 1990. Cautious of this risk, however, the FDA required a black box warning for specific side effects including agranulocytosis, and took the unique step of requiring patients to be registered in a formal system of tracking so that blood count levels could be evaluated on a systematic basis.[29][31]

In December 2002, clozapine was approved in the US for reducing the risk of suicide in people with schizophrenia or

schizoaffective judged to be at chronic risk for suicidal behavior.[32] In 2005, the FDA approved criteria to allow reduced blood monitoring frequency.[33] In 2015, the individual manufacturer Patient Registries were consolidated by request of the FDA into a single shared Patient Registry Called The Clozapine REMS Registry.[34] Despite the demonstrated safety of the new FDA monitoring requirements, which have lower neutrophil levels and do not include total white cell counts, international monitoring has not been standardised.[35][36][37]

Chemistry

Clozapine is a dibenzodiazepine that is structurally very similar to loxapine (originally deemed a typical antipsychotic). It is slightly soluble in water, soluble in acetone, and highly soluble in chloroform. Its solubility in water is 0.1889 mg/L (25 °C).[5] Its manufacturer, Novartis, claims a solubility of <0.01% in water (<100 mg/L).[38]

Clinical uses

Schizophrenia

The role of clozapine in treatment-resistant schizophrenia was established by a 1988 landmark multicenter double blind study[39] in which clozapine (up to 900 mg/d) showed marked benefits compared to chlorpromazine (up to 1800 mg/d) in a group of patients with protracted psychosis who had already shown an inadequate response to at least three previous antipsychotics including a prior single blind trial of haloperidol (mean 61+/− 14 mg/d for six weeks).[30] While there are significant side effects, clozapine remains the most effective treatment when one or more other antipsychotics have had an inadequate response. The use of clozapine is associated with multiple improved outcomes, including a reduced rate of all-cause mortality, suicide and hospitalization.[17][40][41] In a 2013 network comparative meta-analysis of 15 antipsychotic drugs, clozapine was found to be significantly more effective than all other drugs.[42] In a 2021 UK study, the majority of patients (over 85% of respondents) who took clozapine preferred it to their previous therapies, felt better on it and wanted to keep taking it.[43] In a 2000 Canadian survey of 130 patients, the majority reported better satisfaction, quality of life, compliance with treatment, thinking, mood, and alertness.[44][unreliable medical source?]

Clozapine is usually used for people diagnosed with

gold-standard treatment when other medication has been insufficiently effective and its use is recommended by multiple international treatment guidelines, supported by systematic reviews and meta-analysis.[10][11][12][13][14][15][45][46] Whilst all current guidelines reserve clozapine for individuals in whom two other antipsychotics have already been tried, evidence indicates that clozapine might instead be used as a second line drug.[9] Clozapine treatment has been demonstrated to produce improved outcomes in multiple domains including; a reduced risk of hospitalisation, a reduced risk of drug discontinuation, a reduction in overall symptoms and has improved efficacy in the treatment of positive psychotic symptoms of schizophrenia.[40][41][47][48] Despite a range of side effects patients report good levels of satisfaction and long term adherence is favourable compared to other antipsychotics.[49] Very long term follow-up studies reveal multiple benefits in terms of reduced mortality,[17][50] with a particularly strong effect for reduced death by suicide, clozapine is the only antipsychotic known to have an effect reducing the risk of suicide or attempted suicide.[51] Clozapine has a significant anti-aggressive effect.[52][53][54][55][56] Clozapine is widely used in secure and forensic mental health settings where improvements in aggression, shortened admission and reductions in restrictive practice such as seclusion have been found.[57][58][59][60][61][62][63][64][65] In secure hospitals and other settings clozapine has also been used in the treatment of borderline and antisocial personality disorder when this has been associated with violence or self-harm.[66][67][52] Although oral treatment is almost universal clozapine has on occasion been enforced using either nasogastric or a short acting injection although in almost 50% of the approximately 100 reported cases patients agreed to take oral medication prior to the use of a coercive intervention.[58][68][60][69][70][71][62][72][61][73] Clozapine has also been used off-label to treat catatonia with success in over 80% of cases.[74]

Bipolar disorder

On the basis of systematic reviews clozapine is recommended in some treatment guidelines as a third or fourth line treatment for bipolar disorder.[75][76][77][78] A long term follow-up study showed efficacy in terms of both psychiatric and somatic hospitialisation, but with bipolar disorder this effect was not as strong as with some other treatments (olanzapine long-acting injection (LAI) (aHR = 0.54, 95% CI 0.37–0.80), haloperidol LAI (aHR = 0.62, 0.47–0.81), zuclopenthixol LAI (aHR = 0.66, 95% CI 0.52–0.85), lithium (aHR = 0.74, 95% CI 0.71–0.76) and clozapine (aHR = 0.75, 95% CI 0.64–0.87)).[79] Bipolar disorder is an off-label indication for clozapine.[citation needed]

Severe personality disorders

Clozapine is also used in emotionally unstable personality disorder and a randomised controlled trial is currently underway.[80][81][82][83][67][84][85][66][86] The use of clozapine to treat personality disorder is uncommon and off-label.

Initiation

Whilst clozapine is usually initiated in hospital setting community initiation is also available.[87][88] Before clozapine can be initiated multiple assessments and baseline investigations are performed. In the UK and Ireland there must be an assessment that the patient satisfies the criteria for prescription; treatment resistant schizophrenia, intolerance due to extrapyramidal symptoms of other antipsychotics or psychosis in Parkinson's disease. Establishing a history of treatment resistance may include careful review of the medication history including the durations, doses and compliance of previous antipsychotic therapy and that these did not have an adequate clinical effect. A diagnostic review may also be performed. That could include review of antipsychotic plasma concentrations if available. The prescriber, patient, pharmacy and the laboratory performing blood counts are all registered with a specified clozapine provider who must be advised that there is no history of neutropenia from any cause. The clozapine providers collaborate by sharing information regarding patients who have had clozapine related neutropenia or agranulocytosis so that clozapine cannot be used again on license. Clozapine may only be dispensed after a satisfactory blood result has been received by the risk monitoring agency at which point an individual prescription may be released to an individual patient only.[89]

Baseline tests usually also include; a physical examination including baseline weight,

BNP and for neuroleptic malignant syndrome CK.[88]

The dose of clozapine is initially low and gradually increased over a number of weeks. Initial doses may range from 6.5 to 12.5 mg/d increasing stepwise typically to doses in the range of 250–350 mg per day at which point an assessment of response will be performed.[90] In the UK the average clozapine dose is 450 mg/d.[91][92] But response is highly variable and some patients respond at much lower doses and vice versa.

Monitoring

During the initial dose titration phase the following are typically monitored, usually daily at first: pulse, blood pressure, and temperature. Since orthostatic hypotension can be problematic, blood pressure should be monitored both sitting and standing. If there is a significant drop then the rate of the dose increase may be slowed.[88]

Mandatory full blood counts are performed weekly for the first 18 weeks. In some services there will also be monitoring of markers that might indicate myocarditis, troponin, CRP and BNP, although the exact tests and frequency vary between services. Weight is usually measured weekly.

Thereon other investigations and monitoring will always include full blood counts (fortnightly for 1 year then monthly). Weight, waist circumference, lipids and glucose or HbA1c may also be monitored.

Clozapine response and treatment optimisation

As with other antipsychotics, and in contrast to received wisdom, responses to clozapine are typically seen soon after initiation and often within the first week.[93][94] That said responses, especially those which are partial, can be delayed.[95] Quite what an adequate trial of clozapine is, is uncertain but a recommendation is that this should be for at least 8 weeks on a plasma trough level above 350-400 micro g/L.[96][97] There is considerable inter-individual variation. A significant number of patients respond at lower and also much higher plasma concentrations and some patients, especially young male smokers may never achieve these plasma levels even at doses of 900 mg/day. Options then include either increasing the dose above the licensed maximum or the addition of a drug that inhibits clozapine metabolism. Avoiding unnecessary polypharmacy is a general principle in drug treatment.

Optimising blood sampling

The neutrophil cut off for clozapine have shown an exceptional ability to mitigate the risk of neutropenia and agranulocytosis. There is a significant margin of safety. Some patients may have marginal neutrophil counts before and after initiation and they are at risk of premature clozapine discontinuation. A knowledge of neutrophil biology allows blood sampling optimisation. Neutrophils show a diurnal variation in response to the natural cycle of G-CSF production, they are increased in the afternoons, they are also mobilised into the circulation after exercise and smoking. Simply shifting blood sampling has been shown to avoid unnecessary discontinuations, especially in black populations. However this is a disruption to usual hospital practice. Other practical steps are to ensure that blood results become available in hours and when senior staff are available.[59]

Underuse of clozapine

Clozapine is widely recognised as being underused with wide variation in prescribing,[98][99][100][101][102][103][104][105] especially in patients with African heritage.[106][107][108][109][110]

Psychiatrists' prescribing practices have been found to be the most significant variable regarding variance in its use.[citation needed] Surveys of psychiatrists' attitudes to clozapine have found that many had little experience in its use, overestimated the incidence of side effects, and did not appreciate that many patients prefer to take clozapine over other antipsychotics.[111][112][113] In contrast to many psychiatrists' expectations most patients believe that the blood testing and other difficulties are worth the multiple benefits that they perceive.[43][44] Whilst psychiatrists fear the severe adverse effects such as agranulocytosis, patients are more concerned about hypersalivation.[114] Clozapine is no longer actively marketed and this may also be one of the explanations for its underuse.[115]

Despite the strong evidence and universal endorsement by national and international treatment guidelines and the experiences of patients themselves, most people eligible for clozapine are not treated with it.[43] A large study in England found that approximately 30% of those eligible for clozapine were being treated with it.[116] Those patients that do start clozapine usually face prolonged delay, multiple episodes of psychosis and treatments such as high dose antipsychotics or polypharmacy. Instead of two previous antipsychotics many will have been exposed to ten or more drugs which were not effective. A study of 120 patients conducted in four hospitals in South-East London found a mean of 9.2 episodes of antipsychotic prescription before clozapine was initiated and the mean delay in using clozapine was 5 years.[117] Treatments that have no evidence base or are regarded as actively harmful are used instead.[118]

Racial disparity in the use of clozapine

A general finding in healthcare provision is that minority groups receive inferior treatment; this is a particular finding in the US.

benign ethnic neutropenia
.

Benign ethnic neutropenia

Benign reductions in neutrophils are observed in individuals of all ethnic backgrounds ethnic neutropenia (BEN), neutropenia without immune dysfunction or increased liability to infection is not due to abnormal neutrophil production; although, the exact aetiology of the reduction in circulating cells remains unknown. BEN is associated with several ethnic groups, but in particular those with Black African and West African ancestry.[124] A difficulty with the use of clozapine is that neutrophil counts have been standardised on white populations.[125] For significant numbers of black patients the standard neutrophil count thresholds did not permit clozapine use as the thresholds did not take BEN into account. Since 2002, clozapine monitoring services in the UK have used reference ranges 0.5 × 109/l lower for patients with haematologically confirmed BEN and similar adjustments are available in the current US criteria, although with lower permissible minima.[64][36][126] But even then significant numbers of black patients will not be eligible even though the low neutrophil counts do not in their case reflect disease. The Duffy–Null polymorphism, which protects against some types of malaria, is predictive of BEN.[127]

Adverse effects

Clozapine may cause serious and potentially fatal adverse effects. Clozapine carries five black box warnings, including (1) severe neutropenia (low levels of neutrophils), (2) orthostatic hypotension (low blood pressure upon changing positions), including slow heart rate and fainting, (3) seizures, (4) myocarditis (inflammation of the heart), and (5) risk of death when used in elderly people with dementia-related psychosis.[4] Lowering of the seizure threshold may be dose related. Increasing the dose slowly may decrease the risk for seizures and orthostatic hypotension.[128]

Common effects include

muscle stiffness, sedation, tremors, orthostatic hypotension, high blood sugar, and weight gain. The risk of developing extrapyramidal symptoms, such as tardive dyskinesia, is below that of typical antipsychotics; this may be due to clozapine's anticholinergic effects. Extrapyramidal symptoms may subside somewhat after a person switches from another antipsychotic to clozapine.[128] Sexual problems, such as retrograde ejaculation, have been reported while taking clozapine.[4] Rare adverse effects include periorbital edema.[129] Despite the risk for numerous side effects, many side effects can be managed while continuing to take clozapine.[130]

Neutropenia and agranulocytosis

Main article:
blood dyscrasias, in particular agranulocytosis, in the first 18 weeks of treatment. After one year, this risk reduces to that associated with most antipsychotics. Clozapine's use is therefore usually reserved for people who have not responded to at least two other antipsychotics and is only done with stringent blood monitoring.[7] Overall, despite the concerns relating to blood and other side effects, clozapine use is associated with a reduced mortality, especially from suicide which is a major cause of premature death in people with schizophrenia.[131] The risk of clozapine related agranulocytosis and neutropenia warranted the mandatory use of stringent risk monitoring and management systems, which have reduced the risk of death from these adverse events to around 1 in 7,700.[132] The association between clozapine use and specific blood dyscrasias was first noted in the 1970s when eight deaths from agranulocytosis were noted in Finland.[27] At the time it was not clear if this exceeded the established rate of this side effect which is also found in other antipsychotics and although the drug was not completely withdrawn, its use became limited.[23]

Clozapine Induced

point-of-care tests may simplify the monitoring for agranulocytosis.[136]

Clozapine rechallenge

A clozapine "rechallenge" is when someone that experienced agranulocytosis while taking clozapine starts taking the medication again. In countries in which the neutrophil thresholds are higher than those used in the US a simple approach is, if the lowest ANC had been above the US cut off, to reintroduce clozapine but with the US monitoring regime. This has been demonstrated in a large cohort of patients in a hospital in London in which it was found that of 115 patients who had had clozapine stopped according to the US criteria only 7 would have had clozapine stopped if the US cut offs had been used. Of these 62 were rechallenged, 59 continued to use clozapine without difficulty and only 1 had a fall in neutrophils below the US cut off.[37] Other approaches have included the use of other drugs to support neutrophil counts including lithium or granulocyte colony-stimulating factor (G-CSF). However, if agranulocytosis still occurs during a rechallenge, the alternative options are limited.[137][138]

Cardiac toxicity

Clozapine can rarely cause myocarditis and cardiomyopathy. A large meta-analysis of clozapine exposure to over 250,000 people revealed that these occurred in approximately 7 in 1000 patients treated and resulted in death in 3 and 4 in 10,000 patients exposed respectively and although myocarditis occurred almost exclusively within the first 8 weeks of treatment, cardiomyopathy can occur much later on.[139] First manifestations of illness are fever which may be accompanied by symptoms associated with upper respiratory tract, gastrointestinal or urinary tract infection. Typically C-reactive protein (CRP) increases with the onset of fever and rises in the cardiac enzyme, troponin, occur up to 5 days later. Monitoring guidelines advise checking CRP and troponin at baseline and weekly for the first 4 weeks after clozapine initiation and observing the patient for signs and symptoms of illness.[140] Signs of heart failure are less common and may develop with the rise in troponin. A recent case-control study found that the risk of clozapine-induced myocarditis is increased with increasing rate of clozapine dose titration, increasing age and concomitant sodium valproate.[141] A large electronic health register study has revealed that nearly 90% of cases of suspected clozapine related myocarditis are false positives.[142] Rechallenge after clozapine induced myocarditis has been performed and a protocol for this specialist approach has been published.[143] A systematic review of rechallenge after myocarditis has shown success in over 60% of reported cases.[144]

Gastrointestinal hypomotility

Another underrecognized and potentially life-threatening effect spectrum is gastrointestinal hypomotility, which may manifest as severe

radiopaque markers.[146] Clozapine-induced gastrointestinal hypomotility currently has a higher mortality rate than the better known side effect of agranulocytosis.[147] A Cochrane review found little evidence to help guide decisions about the best treatment for gastrointestinal hypomotility caused by clozapine and other antipsychotic medication.[148] Monitoring bowel function and the preemptive use of laxatives for all clozapine-treated people has been shown to improve colonic transit times and reduce serious sequelae.[149]

Hypersalivation

Hypersalivation, or the excessive production of saliva, is one of the most common adverse effects of clozapine (30–80%).

muscarinic antagonist at the M1, M2, M3, and M5 receptors, clozapine is a full agonist at the M4 subset. Because M4 is highly expressed in the salivary gland, its M4 agonist activity is thought to be responsible for hypersalivation.[151] clozapine-induced hypersalivation is likely a dose-related phenomenon, and tends to be worse when first starting the medication.[150] Besides decreasing the dose or slowing the initial dose titration, other interventions that have shown some benefit include systemically absorbed anticholinergic medications such as hyoscine,[152] diphenhydramine[150] and topical anticholinergic medications like ipratropium bromide.[153] Mild hypersalivation may be managed by sleeping with a towel over the pillow at night.[153]

Central nervous system

CNS side effects include

antipsychotics, clozapine rarely has been known to cause neuroleptic malignant syndrome.[154]

Urinary incontinence

Clozapine is linked to urinary incontinence,[155] though its appearance may be under-recognized.[156] This side-effect may be amendable to bethanechol.[157]

Withdrawal effects

Abrupt withdrawal may lead to

rebound effects, such as indigestion, diarrhea, nausea/vomiting, overabundance of saliva, profuse sweating, insomnia, and agitation.[158] Abrupt withdrawal can also cause severe movement disorders, catatonia, and psychosis.[159] Doctors have recommended that patients, families, and caregivers be made aware of the symptoms and risks of abrupt withdrawal of clozapine. When discontinuing clozapine, gradual dose reduction is recommended to reduce the intensity of withdrawal effects.[160][161]

Weight gain and diabetes

In addition to

atypical antipsychotics.[163] For people who gain weight because of clozapine, taking metformin may reportedly improve three of the five components of the metabolic syndrome: waist circumference, fasting glucose, and fasting triglycerides.[164]

Pneumonia

International adverse drug effect databases indicate that clozapine use is associated with a significantly increased incidence of and death from pneumonia and this may be one of the most significant adverse events.[165] The mechanisms for this are unknown although it has been speculated that it may be related to hypersalivation or the immune effects of clozapine's effects on the resolution of inflammation.[166][167]

Overdose

Symptoms of overdose can be variable, but often include; sedation, confusion, tachycardia, seizures and ataxia. Fatalities have been reported due to clozapine overdose, though overdoses of greater than 5000 mg have been survived.[168][169]

Drug interactions

Fluvoxamine inhibits the metabolism of clozapine leading to significantly increased blood levels of clozapine.[170]

When carbamazepine is concurrently used with clozapine, it has been shown to decrease plasma levels of clozapine significantly thereby decreasing the beneficial effects of clozapine.[171][172] Patients should be monitored for "decreased therapeutic effects of clozapine if carbamazepine" is started or increased. If carbamazepine is discontinued or the dose of carbamazepine is decreased, therapeutic effects of clozapine should be monitored. The study recommends carbamazepine to not be used concurrently with clozapine due to increased risk of agranulocytosis.[173]

Ciprofloxacin is an inhibitor of CYP1A2 and clozapine is a major CYP1A2 substrate. Randomized study reported elevation in clozapine concentration in subjects concurrently taking ciprofloxacin.[174] Thus, the prescribing information for clozapine recommends "reducing the dose of clozapine by one-third of original dose" when ciprofloxacin and other CYP1A2 inhibitors are added to therapy, but once ciprofloxacin is removed from therapy, it is recommended to return clozapine to original dose.[175]

Pharmacology

Pharmacodynamics

See also: Atypical antipsychotic § Pharmacodynamics, and Antipsychotic § Comparison of medications
Clozapine and
norclozapine binding[176][177]
Protein CZP
Ki
(nM)
Ki
(nM)
5-HT1A 123.7 13.9
5-HT1B 519 406.8
5-HT1D 1,356 476.2
5-HT2A 5.35 10.9
5-HT2B 8.37 2.8
5-HT2C 9.44 11.9
5-HT3 241 272.2
5-HT5A 3,857 350.6
5-HT6 13.49 11.6
5-HT7 17.95 60.1
α1A 1.62 104.8
α1B 7 85.2
α2A 37 137.6
α2B 26.5 95.1
α2C 6 117.7
β1 5,000 6,239
β2 1,650 4,725
D1
 266.25 14.3
D2
 157 101.4
D3
 269.08 193.5
D4
 26.36 63.94
D5
 255.33 283.6
H1 1.13 3.4
H2 153 345.1
H3 >10,000 >10,000
H4 665 1,028
M1 6.17 67.6
M2 36.67 414.5
M3 19.25 95.7
M4 15.33 169.9
M5 15.5 35.4
SERTTooltip Serotonin transporter 1,624 316.6
NETTooltip Norepinephrine transporter 3,168 493.9
DATTooltip Dopamine transporter >10,000 >10,000
The smaller the value, the more strongly the drug binds to the site. All data are for cloned human proteins.[176][177]

Clozapine is classified as an atypical antipsychotic drug because it binds to serotonin as well as dopamine receptors.[178] It acts as an antagonist at both receptors.

Clozapine is an antagonist at the 5-HT2A subtype of the serotonin receptor, putatively improving depression, anxiety, and the negative cognitive symptoms associated with schizophrenia.[179][180]

A direct interaction of clozapine with the GABAB receptor has also been shown.[181] GABAB receptor-deficient mice exhibit increased extracellular dopamine levels and altered locomotor behaviour equivalent to that in schizophrenia animal models.[182] GABAB receptor agonists and positive allosteric modulators reduce the locomotor changes in these models.[183]

Clozapine induces the release of glutamate and

reduces the expression of astrocytic glutamate transporters. These are direct effects that are also present in astrocyte cell cultures not containing neurons. Clozapine prevents impaired NMDA receptor expression caused by NMDA receptor antagonists.[185]

Pharmacokinetics

N-desmethylclozapine (norclozapine), clozapine's major active metabolite.

The absorption of clozapine is almost complete following oral administration, but the oral

elimination half-life of clozapine is about 14 hours at steady state conditions (varying with daily dose).[medical citation needed
]

Clozapine is extensively metabolized in the liver, via the

isoenzyme 1A2 is primarily responsible for clozapine metabolism, but 2C, 2D6, 2E1 and 3A3/4 appear to play roles as well. Agents that induce (e.g., cigarette smoke) or inhibit (e.g., theophylline, ciprofloxacin, fluvoxamine) CYP1A2 may increase or decrease, respectively, the metabolism of clozapine. For example, the induction of metabolism caused by smoking means that smokers require up to double the dose of clozapine compared with non-smokers to achieve an equivalent plasma concentration.[187]

Clozapine and norclozapine (desmethyl-clozapine) plasma levels may also be monitored, though they show a significant degree of variation and are higher in women and increase with age.[188] Monitoring of plasma levels of clozapine and norclozapine has been shown to be useful in assessment of compliance, metabolic status, prevention of toxicity, and in dose optimisation.[187]

List of trade names for clozapine[1]
A Alemoxan, Azaleptine, Azaleptol
C Cloment, Clonex, Clopin, Clopine, Clopsine, Cloril, Clorilex, Clozamed, Clozapex, Clozapin, Clozapina, Clozapinum, Clozapyl, Clozarem, Clozaril
D Denzapine, Dicomex
E Elcrit, Excloza
F FazaClo, Froidir
I Ihope
K Klozapol
L Lanolept, Lapenax, Leponex, Lodux, Lozapine, Lozatric, Luften
M Medazepine, Mezapin
N Nemea, Nirva
O Ozadep, Ozapim
R Refract, Refraxol
S Sanosen, Schizonex, Sensipin, Sequax, Sicozapina, Sizoril, Syclop, Syzopin
T Tanyl
U Uspen
V Versacloz
X Xenopal
Z Zaclo, Zapenia, Zapine, Zaponex, Zaporil, Ziproc, Zopin

Economics

Despite the expense of the risk monitoring and management systems required, clozapine use is highly cost effective; with a number of studies suggesting savings of tens of thousands of dollars per patient per year compared to other antipsychotics as well as advantages regarding improvements in quality of life.

generic medication.[19]

References

  1. ^ a b "Clozapine International Brands". Drugs.com. Archived from the original on 1 March 2017. Retrieved 28 February 2017.
  2. FDA
    . Retrieved 22 October 2023.
  3. ^ Anvisa (31 March 2023). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 4 April 2023). Archived from the original on 3 August 2023. Retrieved 16 August 2023.
  4. ^ a b c "Clozaril- clozapine tablet". DailyMed. Retrieved 17 August 2021.
  5. ^
    PMID 19117422
    .
  6. OCLC 1222779588
    .
  7. ^ a b c "Clozaril 25 mg Tablets - Summary of Product Characteristics (SmPC)". www.medicines.org.uk. Retrieved 14 September 2021.
  8. ^
    OCLC 1105250833
    .
  9. ^
    S2CID 52014623
    .
  10. ^
    S2CID 20370225
    .
  11. ^
    PMID 19955390
    .
  12. ^
    PMID 16135862
    .
  13. ^
    S2CID 44282161
    .
  14. ^
    PMID 27919182
    .
  15. ^
    PMID 27106681
    .
  16. PMID 28703015
    .
  17. ^
    PMID 31922669
    .
  18. hdl:10665/325771
    . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  19. ^ a b c d "Clozapine". The American Society of Health-System Pharmacists. Archived from the original on 8 December 2015. Retrieved 1 December 2015.
  20. S2CID 198912192
    .
  21. PMID 22893011
    .
  22. ^ "Clozaril, Fazaclo ODT, Versacloz (clozapine): Drug Safety Communication - FDA Strengthens Warning That Untreated Constipation Can Lead to Serious Bowel Problems". FDA. 28 January 2020. Retrieved 30 January 2020.
  23. ^
    S2CID 21086497
    .
  24. ISBN 978-3-0348-8448-8
    – via Google Books.
  25. S2CID 54345964
    .
  26. S2CID 24782844
    .
  27. ^
    S2CID 53296036
    .
  28. PMID 30767710
    .
  29. ^
    S2CID 5007914
    .
  30. ^
    PMID 3046553
    .
  31. ISBN 978-0-203-73615-9
    .
  32. ^ "Supplemental NDA Approval Letter for Clozaril, NDA 19-758 / S-047" (PDF). United States Food and Drug Administration. 18 December 2002. Archived from the original (PDF) on 8 November 2013. Retrieved 23 November 2012.
  33. ^ "Letter to Novartis Pharmaceuticals Corporation" (PDF). Archived (PDF) from the original on 11 May 2011. Retrieved 20 September 2009.
  34. ^ "FDA Modifies REMS Program for Clozapine". www.raps.org. Retrieved 14 August 2021.
  35. PMID 28742291
    .
  36. ^
    S2CID 23395968
    .
  37. ^
    PMID 33543755
    .
  38. ^ Novartis Pharmaceuticals (April 2006). "Prescribing Information" (PDF). Novartis Pharmaceuticals. p. 36. Archived from the original on 23 October 2008. Retrieved 29 June 2007.
  39. ^ "clozapine (CHEBI:3766)". www.ebi.ac.uk. Retrieved 1 October 2021.
  40. ^
    PMID 31365048
    .
  41. ^
    S2CID 241225484
    .
  42. S2CID 32085212
    .
  43. ^
    ISSN 0955-6036
    .
  44. ^
    PMID 10783189
    .
  45. PMID 19160174
    .
  46. PMID 27388573
    .
  47. PMID 21052043
    .
  48. S2CID 59603040
    .
  49. S2CID 36098336
    .
  50. S2CID 27282281
    .
  51. PMID 33428766
    .
  52. ^
    PMID 24698103
    .
  53. PMID 16754835
    .
  54. doi:10.1002/cbm.304
    .
  55. S2CID 2190383
    .
  56. PMID 22339930
    .
  57. ISSN 1355-5146
    .
  58. ^
    doi:10.1192/apt.bp.116.016147
    .
  59. ^
    PMID 32503471
    .
  60. ^
    PMID 30223913
    .
  61. ^
    S2CID 2926142
    .
  62. ^
    PMC 3332745
    .
  63. S2CID 58172685
    .
  64. ^
    PMID 34221348
    .
  65. S2CID 199026883
    .
  66. ^
    S2CID 144701732
    .
  67. ^
    S2CID 43305
    .
  68. PMID 32081110
    .
  69. S2CID 220287156
    .
  70. PMID 10505595
    .
  71. PMID 17928054
    .
  72. S2CID 73372315
    .
  73. PMID 11097649
    .
  74. S2CID 252276294
    .
  75. S2CID 22689570
    .
  76. S2CID 27827654
    .
  77. PMID 27262046
    .
  78. PMID 29536616
    .
  79. PMID 37395140
    .
  80. PMID 34495494
    .
  81. PMID 24812651
    .
  82. PMID 23638443
    .
  83. PMID 27761261
    .
  84. S2CID 26203378
    .
  85. PMID 32504127
    .
  86. ^ "NIHR Funding and Awards Search Website". fundingawards.nihr.ac.uk. Retrieved 14 September 2021.
  87. PMID 32885238
    .
  88. ^
    S2CID 36409113
    .
  89. ^ "Clozaril 25 mg Tablets - Summary of Product Characteristics (SmPC) - (emc)". www.medicines.org.uk. Retrieved 15 September 2021.
  90. ^
    OCLC 1029071684
    .
  91. S2CID 25337120
    .
  92. PMID 30345070
    .
  93. S2CID 2382648
    .
  94. PMID 15863796
    .
  95. ISBN 978-3-8055-9511-7
    .
  96. S2CID 25525638
    .
  97. PMID 9286183
    .
  98. ISSN 1355-5146
    .
  99. PMID 24233347
    .
  100. ISSN 0955-6036
    .
  101. ISSN 0955-6036
    .
  102. PMID 12668398
    .
  103. S2CID 40842497
    .
  104. PMID 23367500
    .
  105. S2CID 235854803
    .
  106. PMID 17170061
    .
  107. ^
    PMID 16399976
    .
  108. ^
    PMID 14514496
    .
  109. PMID 17017827
    .
  110. S2CID 28714732
    .
  111. doi:10.1192/pb.29.10.377
    .
  112. S2CID 34614417
    .
  113. PMID 18211398
    .
  114. S2CID 20487762
    .
  115. doi:10.3371/csrp.1.1.8
    .
  116. ISSN 0955-6036
    .
  117. PMID 12590620
    .
  118. PMID 14600298
    .
  119. ^ Pearl R. "Why Health Care Is Different If You're Black, Latino Or Poor". Forbes. Retrieved 16 September 2021.
  120. ^ "Racism in healthcare: Statistics and examples". www.medicalnewstoday.com. 17 September 2020. Retrieved 16 September 2021.
  121. ^ Bulatao RA, Anderson NB, et al. (National Research Council (US) Panel on Race, Ethnicity, and Health in Later Life) (2004). Stress. National Academies Press (US).
  122. S2CID 204881868
    .
  123. PMID 17017827
    .
  124. PMID 31255364
    .
  125. PMID 10385477
    .
  126. PMID 16143678
    .
  127. PMID 19180233
    .
  128. ^ a b "Clozapine". Pharmacology: MCQs. Archived from the original on 10 November 2013 – via Google Sites.
  129. S2CID 252088054
    .
  130. PMID 23842012
    .
  131. PMID 29697804
    .
  132. ^
    S2CID 75137940
    .
  133. ^
    S2CID 29157011
    .
  134. ^ "A Guide for Patients and Caregivers: What You Need to Know About Clozapine and Neutropenia" (PDF). Clozapine REMS. Clozapine REMS Program. Archived (PDF) from the original on 22 December 2017. Retrieved 14 September 2021.
  135. S2CID 81977064
    .
  136. PMID 31692521
    .
  137. PMID 28747065
    .
  138. S2CID 41269943. Archived from the original
    on 14 May 2023. Retrieved 22 September 2021.
  139. S2CID 210831575
    .
  140. S2CID 26627093
    .
  141. S2CID 25720157
    .
  142. S2CID 236297166
    .
  143. S2CID 231926010
    .
  144. S2CID 237461869
    .
  145. PMID 18452342
    .
  146. PMID 27077119
    .
  147. PMID 23140648
    .
  148. PMID 28116777
    .
  149. S2CID 46825178
    .
  150. ^
    PMID 18646130
    .
  151. ^ "Treatment of Clozapine-Induced Sialorrhea". Archived from the original on 9 February 2012. Retrieved 8 February 2010.
  152. S2CID 58554168
    .
  153. ^
    S2CID 42222976
    .
  154. ^ "ClozarilSide Effects & Drug Interactions". RxList. Archived from the original on 4 November 2007. Retrieved 4 June 2020.
  155. PMID 22122392
    .
  156. PMID 22215862
    .
  157. ^ Dadlani N, Austin M. Bethanechol and Aripiprazole for the management of refractory urinary incontinence in a patient on Clozapine. Aust N Z J Psychiatry. 2016 Feb;50(2):182. doi: 10.1177/0004867415583878. Epub 2015 Apr 28. PMID 25922356.
  158. PMID 23753931
    .
  159. PMID 20587767
    .
  160. PMID 9771818
    .
  161. PMID 10786215
    .
  162. PMID 10401912
    .
  163. S2CID 205678886
    .
  164. PMID 27304831
    .
  165. PMID 31901099
    .
  166. PMID 30259827
    .
  167. PMID 32987640
    .
  168. PMID 11913673
    .
  169. S2CID 28623410
    .
  170. S2CID 36883635
    .
  171. S2CID 260249900
    .
  172. S2CID 45735414
    .
  173. S2CID 31325882
    .
  174. S2CID 20390680
    .
  175. ^ Prescribing information. Clozaril (clozapine). East Hanover, NJ: Novartis Pharmaceuticals Corporation, September 2014.
  176. ^ a b Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  177. ^ a b Roth BL, Driscol J. "PDSP Ki Database". Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. Retrieved 14 August 2017.
  178. S2CID 13021800
    .
  179. ^ Robinson DS (2007). "CNS Receptor Partial Agonists: A New Approach to Drug Discovery". Primary Psychiatry. 14 (8): 22–24. Archived from the original on 18 January 2012.
  180. ^ "Clozapine | C18H19ClN4". PubChem. U.S. Library of Medicine. Archived from the original on 24 December 2013. Retrieved 16 July 2017.
  181. S2CID 277293
    .
  182. S2CID 19780444
    .
  183. PMID 21371011
    .
  184. PMID 21880034
    .
  185. PMID 21326193
    .
  186. S2CID 45731786
    .
  187. ^
    S2CID 31923731
    .
  188. PMID 10074876
    .
  189. PMID 11743592
    .
  190. PMID 32459356
    .
  191. S2CID 33530440
    .

Further reading